Cargando…
Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus
BACKGROUND: A novel urine lipoarabinomannan assay (FujiLAM) has higher sensitivity and higher cost than the first-generation AlereLAM assay. We evaluated the cost-effectiveness of FujiLAM for tuberculosis testing among hospitalized people with human immunodeficiency virus (HIV), irrespective of symp...
Autores principales: | Reddy, Krishna P, Denkinger, Claudia M, Broger, Tobias, McCann, Nicole C, Gupta-Wright, Ankur, Kerkhoff, Andrew D, Pei, Pamela P, Shebl, Fatma M, Fielding, Katherine L, Nicol, Mark P, Horsburgh, C Robert, Meintjes, Graeme, Freedberg, Kenneth A, Wood, Robin, Walensky, Rochelle P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492225/ https://www.ncbi.nlm.nih.gov/pubmed/33200169 http://dx.doi.org/10.1093/cid/ciaa1698 |
Ejemplares similares
-
Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy
por: Matoga, Mitch M, et al.
Publicado: (2021) -
Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study
por: Broger, Tobias, et al.
Publicado: (2019) -
Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data
por: Broger, Tobias, et al.
Publicado: (2020) -
Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts
por: Neilan, Anne M, et al.
Publicado: (2020) -
“SILVAMP TB LAM” Rapid Urine Tuberculosis Test Predicts Mortality in Patients Hospitalized With Human Immunodeficiency Virus in South Africa
por: Sossen, Bianca, et al.
Publicado: (2020)